Insmed reported $-297.13M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Dynavax Technologies USD 35.53M 10.9M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Insmed USD -297.13M 71.11M Jun/2025
Novartis USD 5.84B 235M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025